Animals were randomly assigned into the following groups (12 rats per each
group):
Group I (Control untreated Group): Rats received daily 1 mL saline
i.p. + 1 mL saline orally for 6 weeks.
Group II (Control Valsartan Treated Group): Rats received valsartan
orally in a dose of 20 mg/kg/day for 6 weeks.
Group III (Control Sacubitril/valsartan Treated Group): Rats
received sacubitril/valsartan orally in a dose of 40 mg/kg/day for 6 weeks.
Group IV (Model Group): Rats received aluminum chloride i.p. in a
dose of 10 mg/kg/day for 6 weeks as a positive control model for induction of
AD.9 (link)Group V (Model Valsartan Treated Group): Rats received aluminum
chloride as in group IV and concomitantly treated with valsartan, as previously
mentioned in Group II, for 6 weeks.
Group VI (Model Sacubitril/valsartan Treated Group): Rats received
aluminum chloride as in Group IV and concomitantly treated with
sacubitril/valsartan as previously mentioned in group III for 6 weeksSupplementary Table 1 .
** Doses of the drugs are calculated from human doses according to the body
surface area (BSA) formula.10
group):
i.p. + 1 mL saline orally for 6 weeks.
orally in a dose of 20 mg/kg/day for 6 weeks.
received sacubitril/valsartan orally in a dose of 40 mg/kg/day for 6 weeks.
dose of 10 mg/kg/day for 6 weeks as a positive control model for induction of
AD.9 (link)
chloride as in group IV and concomitantly treated with valsartan, as previously
mentioned in Group II, for 6 weeks.
aluminum chloride as in Group IV and concomitantly treated with
sacubitril/valsartan as previously mentioned in group III for 6 weeks
** Doses of the drugs are calculated from human doses according to the body
surface area (BSA) formula.10
